Pharvaris

PHVS

Market cap $1.49B

Overview Fund Activity

23.20 USD

-0.30

1.28%

At close Updated Sep 12, 4:00 PM EDT

1 day

-1.28%

5 days

-3.29%

1 month

10%

3 months

34.65%

6 months

44.91%

Year to date

25.13%

1 year

13.06%

5 years

-20%

10 years

-20%

About: Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Employees: 114

Healthcare Biotechnology

0

Funds holding %

of 7,462 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

800% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 1

19% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 16

15% more funds holding

Funds holding: 52 [Q1] → 60 (+8) [Q2]

12% more capital invested

Capital invested by funds: $706M [Q1] → $793M (+$87.2M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 6 [Q1] → 6 (+0) [Q2]

0.55% less ownership

Funds ownership: 83.21% [Q1] → 82.66% (-0.55%) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$52

124% upside

Avg. target

$52

124% upside

High target

$52

124% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

JMP Securities

Jonathan Wolleben

$52

Market Outperform

Maintained

13 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about PHVS published over the past 30 days

Pharvaris N.V. (PHVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Pharvaris N.V. (NASDAQ:PHVS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 8:30 AM EDT Company Participants Berndt A.

Pharvaris N.V. (PHVS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Pharvaris N.V. (PHVS) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Pharvaris N.V. (NASDAQ:PHVS ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 3:45 PM EDT Company Participants Peng Lu - Chief Medical Officer Conference Call Participants Tiago Fauth - Wells Fargo Securities, LLC, Research Division Presentation Tiago Fauth Equity Analyst My name is Tiago Fauth.

Pharvaris N.V. (PHVS) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Pharvaris N.V. (PHVS) Presents At Cantor Global Healthcare Conference 2025 Transcript

Pharvaris N.V. (NASDAQ:PHVS ) Cantor Global Healthcare Conference 2025 September 3, 2025 11:30 AM EDT Company Participants Wim Souverijns - Chief Commercial Officer Peng Lu - Chief Medical Officer Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Presentation Steven Seedhouse MD & Biotechnology Analyst Okay.

Pharvaris N.V. (PHVS) Presents At Cantor Global Healthcare Conference 2025 Transcript

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

Topline results for RAPIDe-3, a pivotal Phase 3 study of deucrictibant for the on-demand treatment of HAE attacks, expected in 4Q2025 Enrollment continues in CHAPTER-3, a pivotal Phase 3 study of deucrictibant for prophylaxis of HAE attacks; topline results expected in 2H2026 Startup activities for CREAATE, a pivotal Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks, on track; study is expected to initiate by YE2025 Strong financial position with cash and cash equivalents of €200 million as of June 30, 2025; subsequent closing of $201 million public offering extends cash runway into 1H2027 ZUG, Switzerland, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today reported financial results for the second quarter ended June 30, 2025, and provided a business update. “Halfway through 2025, an important executional year for the company, Pharvaris is making meaningful progress in our ambition to address unmet needs of people living with bradykinin-mediated angioedema,” said Berndt Modig, Chief Executive Officer of Pharvaris.

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations

Pharvaris is advancing deucrictibant, an oral bradykinin B2-receptor antagonist, in two late-stage trials for hereditary angioedema patient populations. Key catalysts include RAPIDe-3 phase 3 topline data in Q4 2025 for on-demand HAE and CHAPTER-3 prophylaxis data expected in the second half of 2026. Deucrictibant's unique oral formulation and dual-use potential could capture significant market share in the $19.68B HAE market if trials are successful.

Pharvaris: Deucrictibant Advanced To Target Two Sets Of HAE Patient Populations

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today the pricing of an underwritten offering of (i) 8,250,000 of its ordinary shares at a price of $20.00 per share and (ii) to one investor, pre-funded warrants to purchase 500,000 ordinary shares at a price of $19.99 per pre-funded warrant, which represents the per share public offering price for the ordinary shares less the $0.01 per share exercise price for each such pre-funded warrant. All shares and pre-funded warrants in the offering are to be sold by Pharvaris. In addition, Pharvaris has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 ordinary shares at the public offering price, less underwriting discounts and commissions. The gross proceeds to Pharvaris from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $175 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about July 24, 2025, subject to satisfaction of customary closing conditions.

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Pharvaris Announces Proposed Public Offering of Ordinary Shares

ZUG, Switzerland, July 22, 2025 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced today that it intends to offer and sell $150,000,000 of ordinary shares in an underwritten public offering. All shares in the offering are to be sold by Pharvaris. In addition, Pharvaris intends to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of ordinary shares. Pharvaris currently intends to use the net proceeds of this offering primarily to fund research and development expenses for its late-stage clinical programs, the hiring of a sales and marketing team in the U.S. and related commercialization expenses and for working capital and general corporate purposes. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Pharvaris Announces Proposed Public Offering of Ordinary Shares

Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success

Pharvaris is a late-stage biopharma that specializes in the treatment of hereditary angioedema (HAE). They have only one drug in their pipeline, deucrictibant, of which they are making two oral formulations: an immediate-release capsule for acute attacks and a daily extended-release tablet. Phase 3 results for the immediate-release capsules (Rapide-3) are expected in Q4 2025.

Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

ZUG, Switzerland, July 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), updated the guidance for the disclosure of topline data from the ongoing RAPIDe-3 pivotal Phase 3 study evaluating deucrictibant immediate-release (IR) capsule for the on-demand treatment of HAE attacks. Pharvaris anticipates announcing topline data from RAPIDe-3 in the fourth quarter of 2025 and, pending positive data, expects to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) in the first half of 2026.

Pharvaris Updates Timing of Topline Data Announcement for RAPIDe-3 Pivotal Phase 3 Study to the Fourth Quarter of 2025

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

ZUG, Switzerland, June 27, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at the US Hereditary Angioedema Association's 2025 National Summit to be held from July 10-13, 2025, in Baltimore, Maryland.

Pharvaris Announces Clinical Trial Data Highlighting Deucrictibant for the Treatment of HAE to be Presented at the 2025 US HAEA National Summit

See News Rankings

Charts implemented using Lightweight Charts™